Genetically modified t cells take aim at Hard-to-Treat blood cancers
NCT ID NCT03081910
First seen Jun 26, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new type of immunotherapy for people with T-cell leukemia or lymphoma that has returned. The treatment involves taking a patient's own immune cells (or cells from a past stem cell donor), adding a special receptor that targets a protein called CD5 found on cancer cells, and infusing them back to fight the disease. The main goal is to check safety and find the right dose, with up to 54 participants enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD5-targeting CAR T cells (a type of immune cell therapy)
- What this could lead to
- If successful, this could point toward a new treatment option for certain T-cell blood cancers that have come back after other treatments.
- What could go wrong
- This is a very early phase 1 trial with only 54 participants, so it is primarily testing safety and dosing. The therapy may not work, and there are risks like severe immune reactions or nerve problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Houston Methodist Hospital
RECRUITINGHouston, Texas, 77030, United States
-
Texas Children's Hospital
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized chemo dosing may boost survival in kids with High-Risk leukemia
- Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
- Engineered immune cells take aim at stubborn blood cancers
- Double-Barreled immune attack aims to wipe out T-ALL
- Chemotherapy showdown: which combo works best for T-Cell cancers in kids?
- Gene test spots hidden leukemia in kids